Zealand Pharma
Company announcement – No. 17 / 2020
Zealand Pharma to participate in upcoming investor conferences
Copenhagen, DK and Boston, MA, U.S. March 25, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in April:
Guggenheim Virtual Healthcare Talks - Genomic Medicines & Rare Disease |
Date: Thursday, April 1, 2021 |
20th Annual Virtual Needham Healthcare Conference |
Date: Monday, April 12, 2021 |
Presentation: 11:45 a.m. ET/ 4:45 p.m. CET |
A live webcast of the Needham event will be available on the "Events & Presentations" page in the Investor section of the Company's website at https://www.zealandpharma.com/events-presentations. A replay of the webcast will be archived on the Company's website following the presentation.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, development, and commercialization of next generation peptide-based medicines that change the lives of people living with metabolic and gastrointestinal diseases. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market. Zealand’s robust pipeline of investigational medicines includes three candidates in late stage development, and one candidate being reviewed for regulatory approval in the United States. Zealand markets V-Go®, an all-in-one basal-bolus insulin delivery option for people with diabetes. License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. Zealand was founded in 1998 in Copenhagen, Denmark, and has presence throughout the U.S. that includes key locations in New York, Boston, and Marlborough (MA). For more information about Zealand’s business and activities, please visit http://www.zealandpharma.com.
For further information, please contact:
Zealand Pharma Investor Relations
Claudia Styslinger
Argot Partners
investors@zealandpharma.com
Zealand Pharma Media Relations
David Rosen
Argot Partners
media@zealandpharma.com
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank8.7.2025 10:15:00 CEST | Press release
RESULT OF RIKSBANK CERTIFICATE SALE
iPronics; Ansys8.7.2025 10:11:00 CEST | Press release
iPronics Collaborates with Ansys to bring reliability to AI Infrastructure and Data Centers
Fanvue8.7.2025 10:06:40 CEST | Press release
“The Grammys” for AI Music? Entries Open for Groundbreaking Song Contest from the Fanvue World AI Creator Awards - as Millions of Creators Make Music with AI
Corbion8.7.2025 10:06:00 CEST | Press release
Corbion secures Chinese regulatory approvals for algae-derived Omega-3 DHA products in human and animal nutrition
Sveriges Riksbank8.7.2025 09:30:00 CEST | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom